Company news
Jiangsu Yahong Meditech Co., Ltd. news in 2025
Jiangsu Yahong Meditech Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Voluntary Disclosure of Acceptance of APLD-2304 for European Medical Device Registration
December 21, 2025
Announcement on Voluntary Disclosure of Clinical Trial Applications for APL-2401 Approved by China NMPA
December 17, 2025
Announcement on Voluntary Disclosure of the Release of APL-1401 Phase Ib Clinical Trial Data at the 19th European Colorectal Congress (ECC)
December 3, 2025
Announcement on Changing Signatory Certified Public Accountant
November 28, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 19, 2025
Announcement on Completing Changes in Registered Capital and Obtaining Renewed Business License
November 14, 2025
Announcement on Election of Employee Directors for the 2nd Board of Directors and Appointment of Senior Management Members
October 29, 2025
Announcement on Voluntary Disclosure of Publication of Relevant Data from the APL-1702 International Multicenter Phase 3 Clinical Trial in the International Journal "Med"
October 10, 2025
Announcement on Departure of Company Director and Senior Management Member
September 30, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 23, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
September 5, 2025
Announcement on Canceling the Board of Supervisors, Changing the Registered Capital, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Formulating and Revising Some Corporate Governance Systems
August 28, 2025
Announcement on Voluntary Disclosure of Positive Preliminary Results from APL-1401 Phase Ib Clinical Trial
July 31, 2025
Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan and Listing of Stocks
July 29, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
July 25, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 4, 2025
Announcement on Listing and Circulation of Some Restricted Stocks in Initial Public Offering
June 27, 2025
Announcement on Resolution of the 12th Meeting of the 2nd Board of Supervisors
June 20, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 23, 2025
Report for Q1 2025
April 29, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing and Q1 2025 Performance Briefing
April 25, 2025
Special Report on Deposit and Actual Use of Raised Funds in 2024
April 18, 2025
Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Phase Ⅰa Clinical Trial for APL-2302
March 13, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium
February 14, 2025
Announcement on Adjustment of Core Technical Personnel
February 7, 2025
Announcement on Opening Special Settlement Accounts for the Cash Management of Raised Funds
January 22, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
January 17, 2025
Announcement on the Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2302 by the National Medical Products Administration
January 16, 2025